Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 15/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984570 | 1.00 | MAPK8 (0.40) | MAPK8MAPK9PIK3CAMAPK3GBA1 | |
| SCHEMBL1984567 | 1.00 | MAPK8 (0.40) | MAPK8MAPK9PIK3CAMAPK3GBA1 | |
| SCHEMBL8202236 | 0.88 | MAPK8 (0.38) | MAPK8MAPK9 | |
| SCHEMBL1984281 | 0.87 | CHUK (0.40) | MAPK8MAPK9ALDH1A1 | |
| SCHEMBL1984278 | 0.87 | CHUK (0.40) | MAPK8MAPK9ALDH1A1 | |
| SCHEMBL8202941 | 0.87 | CHUK (0.40) | MAPK8MAPK9ALDH1A1 | |
| SCHEMBL1984275 | 0.87 | CHUK (0.40) | MAPK8MAPK9ALDH1A1 | |
| SCHEMBL1984119 | 0.86 | PIK3CA (0.40) | PIK3CAJAK1TYK2 | |
| SCHEMBL15453182 | 0.86 | PIK3CA (0.40) | PIK3CAJAK1TYK2 | |
| SCHEMBL1984114 | 0.86 | PIK3CA (0.40) | PIK3CAJAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633204-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2074122-B9 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | PFIZER PROD INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC (US) | 2012-12-06 | — | — | US | disclosed |
| US-8273755-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2074122-B1 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | PFIZER PROD INC (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20100137279-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7696213-B2 | 4-methylpyridopyrimidinone compounds | PFIZER INC (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2074122-A1 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | Pfizer Products Incorporated (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| WO-2008032162-A1 | PYRIDO (2, 3-D) PYRIMIDIN0NE COMPOUNDS AND THEIR USE AS PI3 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090801-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | MAPK8 437/4885MAPK9 172/4885PIK3CA 3/4885 |
| US-20120309775-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | MAPK8 437/4885MAPK9 172/4885PIK3CA 3/4885 |
| US-20100137279-A1 | 4-METHYLPYRIDOPYRIMIDINONE COMPOUNDS | PI4KA, PI4KB, PIK3CA | MAPK8 437/4885MAPK9 172/4885PIK3CA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.